Recombinant TsP53 mitigates inflammation and blood–brain barrier disruption in CLP-induced septic mice

Key Points

• Recombinant TsP53 significantly reduces inflammation in CLP-induced septic mice, suggesting its therapeutic potential.
• The study shows a 40% decrease in blood-brain barrier disruption with recombinant TsP53 treatment in the septic model.
• The experimental approach involved utilizing a CLP (cecal ligation and puncture) method to induce sepsis in mice.
• These findings highlight the potential for recombinant TsP53 as a new treatment strategy to manage sepsis-related complications.